VIR_logo_large.jpg
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
November 12, 2021 08:00 ET | Vir Biotechnology, Inc.
– New data from ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate notable reductions in HBsAg and support their positive safety profiles – SAN FRANCISCO, Nov. 12, 2021 ...
Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021  
November 03, 2021 16:00 ET | INVENTIVA
Presentation of five scientific abstracts selected for poster presentations at the AASLD The Liver Meeting™ 2021 by Prof. Nezam Afdhal and Prof. Jörn SchattenbergUpdate on the current NASH landscape...
Inventiva organise un webcast avec des leaders d’opinion à l’occasion du congrès The Liver Meeting™ 2021 de l’AASLD
November 03, 2021 16:00 ET | INVENTIVA
Revue par les Prof. Nezam Afdhal et Jörn Schattenberg de cinq abstracts présentés  lors du The Liver Meeting™ 2021 de l’AASLDPoint sur le secteur de la NASH par le Prof. Nezam AfdhalPoint d’étape par...
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
October 18, 2021 16:00 ET | INVENTIVA
Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on key components of NASH, following further sub-analyses of Inventiva’s NATIVE Phase IIb clinical trial...
Inventiva annonce la présentation de cinq abstracts scientifiques lors du The Liver Meeting™ 2021 organisé par l’AASLD
October 18, 2021 16:00 ET | INVENTIVA
Quatre présentations par poster confirment les effets bénéfiques de lanifibranor sur des composants clés de la NASH faisant suite à des analyses supplémentaires réalisées sur les résultats de l'étude...
VIR_logo_large.jpg
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
October 15, 2021 08:30 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health...
Arbutus Biopharma Logo
Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting
November 15, 2020 14:40 ET | Arbutus Biopharma Corporation
Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau, suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted...
CocrystalPharmaInc.jpg
Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020
March 30, 2020 06:05 ET | Cocrystal Pharma, Inc.
Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
89biologo.png
89bio Announces Presentations of BIO89-100 Data at The Liver Meeting® 2019
November 11, 2019 09:25 ET | 89bio, Inc.
SAN FRANCISCO and HERZLIYA, Israel, Nov. 11, 2019 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced that two posters related to its...
ritter.jpg
Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance
May 22, 2018 08:30 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...